A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.

Gwenn Hansen Biography and Net Worth

Insider of Nurix Therapeutics

Gwenn M. Hansen, Ph.D. has served as Chief Scientific Officer of Nurix since June 2020 and served as the company’s Senior Vice President, Research from July 2019 through May 2020. Since joining Nurix in 2015, Gwenn has focused on establishing the company’s DNA encoded library technology platform for small molecule discovery in addition to leading the discovery organization. Prior to joining Nurix, Gwenn was an Associate Professor in the Center for Drug Discovery at Baylor College of Medicine and served in a variety of discovery-focused roles at Lexicon Pharmaceuticals. Dr. Hansen holds a B.A. in Biology from Gustavus Adolphus College and a Ph.D. in Biomedical Sciences from the University of Tennessee-Knoxville.

What is Gwenn Hansen's net worth?: The estimated net worth of Gwenn Hansen is at least $656,980.59 as of April 30th, 2024. Dr. Hansen owns 39,601 shares of Nurix Therapeutics stock worth more than $656,981 as of May 20th. This net worth evaluation does not reflect any other assets that Dr. Hansen may own. Additionally, Dr. Hansen receives an annual salary of $702,750.00 as Insider at Nurix Therapeutics. Learn More about Gwenn Hansen's net worth.
How old is Gwenn Hansen?: Dr. Hansen is currently 53 years old. There are 4 older executives and no younger executives at Nurix Therapeutics. The oldest executive at Nurix Therapeutics is Dr. Arthur T. Sands M.D., Ph.D., CEO, President & Director, who is 62 years old. Learn More on Gwenn Hansen's age.
What is Gwenn Hansen's salary?: As the Insider of Nurix Therapeutics, Inc., Dr. Hansen earns $702,750.00 per year. The highest earning executive at Nurix Therapeutics is Dr. Arthur T. Sands M.D., Ph.D., CEO, President & Director, who commands a salary of $986,320.00 per year. Learn More on Gwenn Hansen's salary.
How do I contact Gwenn Hansen?: The corporate mailing address for Dr. Hansen and other Nurix Therapeutics executives is , , . Nurix Therapeutics can also be reached via phone at 415-660-5320 and via email at [email protected]. Learn More on Gwenn Hansen's contact information.
Has Gwenn Hansen been buying or selling shares of Nurix Therapeutics?: During the last ninety days, Gwenn Hansen has sold $24,164.28 in Nurix Therapeutics stock. Most recently, Gwenn Hansen sold 2,007 shares of the business's stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $12.04, for a transaction totalling $24,164.28. Following the completion of the sale, the insider now directly owns 39,601 shares of the company's stock, valued at $476,796.04. Learn More on Gwenn Hansen's trading history.
Who are Nurix Therapeutics' active insiders?: Nurix Therapeutics' insider roster includes Pierre Beaurang (Insider), Gwenn Hansen (Insider), and Christine Ring (General Counsel). Learn More on Nurix Therapeutics' active insiders.
Are insiders buying or selling shares of Nurix Therapeutics?: In the last twelve months, insiders at the sold shares 12 times. They sold a total of 35,477 shares worth more than $350,992.37. The most recent insider tranaction occured on May, 2nd when CFO Houte Hans Van sold 3,499 shares worth more than $44,892.17. Insiders at Nurix Therapeutics own 7.2% of the company. Learn More about insider trades at Nurix Therapeutics.
Information on this page was last updated on 5/2/2024.

Gwenn Hansen Insider Trading History at Nurix Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/30/2024	Sell	2,007	$12.04	$24,164.28	39,601
1/30/2024	Sell	2,334	$7.99	$18,648.66	36,402
7/31/2023	Sell	1,884	$9.65	$18,180.60	29,955
5/1/2023	Sell	1,136	$9.88	$11,223.68	26,632
1/30/2023	Sell	1,412	$11.78	$16,633.36	23,009
10/31/2022	Sell	1,165	$12.88	$15,005.20	21,214
8/1/2022	Sell	1,186	$15.67	$18,584.62	19,172
5/2/2022	Sell	1,098	$11.75	$12,901.50	17,151
12/1/2021	Sell	400	$29.13	$11,652.00
11/1/2021	Sell	400	$33.24	$13,296.00
10/27/2021	Sell	400	$35.00	$14,000.00
10/1/2021	Sell	400	$29.92	$11,968.00
9/7/2021	Sell	1,600	$35.00	$56,000.00	15,797
8/2/2021	Sell	400	$31.21	$12,484.00	14,204
6/1/2021	Sell	400	$27.74	$11,096.00	14,204
4/5/2021	Sell	400	$35.00	$14,000.00	14,204
4/1/2021	Sell	400	$31.55	$12,620.00	14,204
3/16/2021	Sell	800	$45.00	$36,000.00	14,604
3/1/2021	Sell	800	$35.95	$28,760.00

Gwenn Hansen Buying and Selling Activity at Nurix Therapeutics

Nurix Therapeutics Company Overview

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Today's Range

Now: $16.59

$14.53

$16.84

50 Day Range

MA: $14.12

$12.02

$17.48

2 Week Range

Now: $16.59

$4.22

$18.12

Volume

3,038,600 shs

Average Volume

945,510 shs

Market Capitalization

$815.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.1

Elon’s New Device is About to Shock the World

From InvestorPlace | Ad

Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.”

Click here to see the details because there’s a lot of money at stake.

Gwenn Hansen Biography and Net Worth

What is Gwenn Hansen's net worth?

How old is Gwenn Hansen?

What is Gwenn Hansen's salary?

How do I contact Gwenn Hansen?

Has Gwenn Hansen been buying or selling shares of Nurix Therapeutics?

Who are Nurix Therapeutics' active insiders?

Are insiders buying or selling shares of Nurix Therapeutics?